KIT and acute myeloid leukemia: In summary, elevated susceptibility to PU-H71 and S63845 was present in FLT3 mutated AML with CD34 < 20% and to PU-H71 and venetoclax in primary AML with CD117 > 80% and CD11b < 45%.